Survodutide 10mg

Survodutide (BI 456906) is a dual GLP-1/Glucagon receptor agonist developed by Boehringer Ingelheim — one of the most clinically advanced non-semaglutide/tirzepatide weight loss peptides in late-stage development, with a distinct pharmacological profile driven by its significant glucagon receptor agonism alongside GLP-1 receptor activity. The glucagon component fundamentally distinguishes survodutide from pure GLP-1 agonists, adding hepatic fat mobilization and thermogenic metabolic effects that GLP-1 receptor activation alone does not provide.

The molecular mechanism of survodutide reflects its dual receptor profile. GLP-1 receptor agonism provides the established effects of this class: appetite suppression through hypothalamic signaling, delayed gastric emptying that reduces caloric intake and blunts postprandial glucose excursions, improved pancreatic insulin secretion in response to elevated glucose, and cardiovascular protective effects through GLP-1 receptor-expressing cardiac tissue. The simultaneous glucagon receptor agonism adds hepatic triglyceride lipolysis (glucagon drives hepatic fat mobilization), increased thermogenesis through brown adipose tissue activation, and additional hepatic metabolic effects that are particularly relevant for non-alcoholic fatty liver disease (NAFLD/MASH).

This dual activity produces a mechanistically differentiated weight loss and metabolic profile. Clinical trial data from Phase 2 studies demonstrates survodutide's efficacy: the SYNERGY-NASH trial in patients with MASH (metabolic dysfunction-associated steatohepatitis) showed survodutide produced significantly greater hepatic fat reduction than semaglutide comparators, with histological MASH resolution in a substantial proportion of participants. Body weight reduction in Phase 2 obesity trials reached 18–19% at 46 weeks — comparable to tirzepatide and approaching the efficacy ceiling of current GLP-1-based agents, while potentially offering superior hepatic benefits through the glucagon component.

The glucagon receptor agonism in survodutide requires careful pharmacological engineering — excess glucagon signaling drives hyperglycemia by stimulating hepatic glucose production, which would counteract the glucose-lowering GLP-1 component. Survodutide's dose ratio between GLP-1 and glucagon agonism is calibrated to achieve metabolic benefits from glucagon (hepatic fat, thermogenesis) without the glycemic liability, using the glucose-lowering GLP-1 component to offset potential glucagon-driven glucose elevation. This balance makes the ratio of dual agonism as pharmacologically significant as the absolute potency at each receptor.

Survodutide is currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH — making it the most advanced GLP-1/glucagon dual agonist in clinical development. The MASH indication is of particular interest: MASH has extremely limited pharmacological treatment options, and survodutide's ability to combine appetite suppression, weight loss, and direct hepatic fat reduction through glucagon receptor agonism positions it as a potential breakthrough in this unmet need.

Research compound only. Protocol: doses ranging from 0.3mg to 4.8mg SC injection, with dose escalation to therapeutic target. Phase 2 studies used weekly subcutaneous injection.